Insmed Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. LVS
7. SAP
8. CSX
9. LRCX
10. MRK

Go back to Insmed Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

Insmed (INSM) Misses Q4 EPS by 10c, Revenues Beat; Offers FY19 Revenue Outlook Above Consensus

February 22, 2019 7:32 AM EST

Insmed (NASDAQ: INSM) reported Q4 EPS of ($1.16), $0.10 worse than the analyst estimate of ($1.06). Revenue for the quarter came in at $9.8 million versus the consensus estimate of $6.89 million.

"2018 was a pivotal year for Insmed, with the U.S. approval and launch of ARIKAYCE® (amikacin liposome inhalation suspension), the first and only FDA-approved treatment for patients with refractory Mycobacterium avium complex (MAC) lung disease. We are very pleased with the strong momentum we've seen since launch, including a wide breadth of prescribers, steady additions of new patients, and positive reimbursement trends," commented Will Lewis, Chairman... More